ICG Life Sciences

ICG Life Sciences is the dedicated life sciences arm of Intermediate Capital Group, deploying structured equity into clinical-stage biotech and pharmaceutical companies addressing severe unmet needs. The platform leverages ICG’s broader balance sheet and structured credit expertise to offer flexible capital that can sit between traditional venture, royalty financing, and growth equity. The strategy concentrates on therapeutics and large-molecule programs with binary clinical events, where the team underwrites scientific and regulatory risk alongside commercial viability. ICG Life Sciences is not framed as an AI investor, and limited public information is available about current named team members within this specific strategy.

The group invests at Series B, Series C, and Growth stages, writing checks of $25M and above that anchor or co-anchor late-stage rounds for biotech and pharma platforms requiring substantial clinical and commercialization capital. Geographic scope is global from a London base, with active engagement across European and North American clinical-stage assets. ICG typically participates alongside specialist crossover investors, larger life sciences funds, and corporate strategics rather than seeding new companies.

For founders and CEOs, ICG Life Sciences is best understood as a structured capital partner for advanced therapeutic programs rather than an early innovation backer. Companies engaging with the group should expect rigorous scientific, regulatory, and financial diligence, and a willingness to negotiate creative deal structures including preferred equity and milestone-linked tranching. Founders running pre-clinical platforms or seeking small early checks will find ICG out of scope. The right fit is a clinical-stage management team with a credible asset, sophisticated cap table awareness, and the capacity to absorb meaningful institutional capital.